Country: Kanada
Tungumál: enska
Heimild: Health Canada
CARVEDILOL
RANBAXY PHARMACEUTICALS CANADA INC.
C07AG02
CARVEDILOL
12.5MG
TABLET
CARVEDILOL 12.5MG
ORAL
100
Prescription
BETA-ADRENERGIC BLOCKING AGENTS
Active ingredient group (AIG) number: 0122683005; AHFS:
CANCELLED POST MARKET
2022-09-16
PRODUCT MONOGRAPH PR RAN™-CARVEDILOL Carvedilol Tablets, House Standard 3.125, 6.25, 12.5 and 25 mg CONGESTIVE HEART FAILURE AGENT Ranbaxy Pharmaceuticals Canada Inc. DATE OF REVISION: 126 East Drive SEPTEMBER 14, 2016 Brampton, Ontario L4W 0A5 Submission Control No: 197425 RAN trademark owned by Sun Pharmaceutical Industries Ltd. _ _ _RAN-CARVEDILOL Product Monograph _ _ _ _Page 2 of 38 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE .............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................9 DRUG INTERACTIONS ..................................................................................................15 DOSAGE AND ADMINISTRATION ..............................................................................17 OVERDOSAGE ................................................................................................................19 ACTION AND CLINICAL PHARMACOLOGY ............................................................20 STORAGE AND STABILITY ..........................................................................................23 DOSAGE FORMS, COMPOSITION AND PACKAGING ..............................................23 PART II: SCIENTIFIC INFORMATION ...............................................................................25 PHARMACEUTICAL INFORMATION ..........................................................................25 CLINICAL TRIALS ............................................................................................. Lestu allt skjalið